US4288627A
(en)
|
1980-02-12 |
1981-09-08 |
Phillips Petroleum Company |
Oxidation of thiols employing cobalt molybdate/triethylamine catalyst
|
NZ202757A
(en)
|
1981-12-23 |
1985-11-08 |
Novo Industri As |
Peptides and medicaments
|
US5118666A
(en)
|
1986-05-05 |
1992-06-02 |
The General Hospital Corporation |
Insulinotropic hormone
|
US5120712A
(en)
|
1986-05-05 |
1992-06-09 |
The General Hospital Corporation |
Insulinotropic hormone
|
US5614492A
(en)
|
1986-05-05 |
1997-03-25 |
The General Hospital Corporation |
Insulinotropic hormone GLP-1 (7-36) and uses thereof
|
JP3262329B2
(ja)
|
1990-01-24 |
2002-03-04 |
アイ. バックレイ,ダグラス |
糖尿病治療に有用なglp―1アナログ
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
DE69107455T3
(de)
|
1990-05-09 |
2004-09-23 |
Novozymes A/S |
Eine ein endoglucanase enzym enthaltende zellulasezubereitung.
|
DK36392D0
(da)
|
1992-03-19 |
1992-03-19 |
Novo Nordisk As |
Anvendelse af kemisk forbindelse
|
US5846747A
(en)
|
1992-03-25 |
1998-12-08 |
Novo Nordisk A/S |
Method for detecting glucagon-like peptide-1 antagonists and agonists
|
DK39892D0
(da)
|
1992-03-25 |
1992-03-25 |
Bernard Thorens |
Peptid
|
US5424286A
(en)
|
1993-05-24 |
1995-06-13 |
Eng; John |
Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
|
WO1995005848A1
(en)
|
1993-08-24 |
1995-03-02 |
Novo Nordisk A/S |
Protracted glp-1
|
AU7685894A
(en)
|
1993-09-07 |
1995-03-27 |
Amylin Pharmaceuticals, Inc. |
Methods for regulating gastrointestinal motility
|
US5705483A
(en)
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
US5512549A
(en)
|
1994-10-18 |
1996-04-30 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
|
US5523449A
(en)
|
1995-05-17 |
1996-06-04 |
Bayer Corporation |
Process for preparing phosphorodichlorido-dithioates by reacting alkylmercaptans with phosphorus trichloride in the presence of sulfur
|
WO1997046584A1
(de)
|
1996-06-05 |
1997-12-11 |
Boehringer Mannheim Gmbh |
Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel
|
US6110703A
(en)
|
1996-07-05 |
2000-08-29 |
Novo Nordisk A/S |
Method for the production of polypeptides
|
JP2001501593A
(ja)
|
1996-08-08 |
2001-02-06 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
胃腸運動を調節するための方法
|
US6956026B2
(en)
|
1997-01-07 |
2005-10-18 |
Amylin Pharmaceuticals, Inc. |
Use of exendins for the reduction of food intake
|
US6277819B1
(en)
|
1996-08-30 |
2001-08-21 |
Eli Lilly And Company |
Use of GLP-1 or analogs in treatment of myocardial infarction
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US7235627B2
(en)
|
1996-08-30 |
2007-06-26 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
UA72181C2
(uk)
|
1996-08-30 |
2005-02-15 |
Ново Нордіск А/С |
Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US6006753A
(en)
|
1996-08-30 |
1999-12-28 |
Eli Lilly And Company |
Use of GLP-1 or analogs to abolish catabolic changes after surgery
|
IL128828A0
(en)
|
1996-09-09 |
2000-01-31 |
Zealand Pharmaceuticals As |
Peptide prodrugs containing an alpha-hydroxy acid linker
|
ATE290014T1
(de)
|
1996-09-09 |
2005-03-15 |
Zealand Pharma As |
Festphasen-peptidsynthese
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
AU5065198A
(en)
|
1996-11-15 |
1998-06-10 |
Maria Grazia Masucci |
Fusion proteins having increased half-lives
|
US6136784A
(en)
|
1997-01-08 |
2000-10-24 |
Amylin Pharmaceuticals, Inc. |
Amylin agonist pharmaceutical compositions containing insulin
|
US6410511B2
(en)
|
1997-01-08 |
2002-06-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
EP0981611A1
(en)
|
1997-02-05 |
2000-03-01 |
1149336 Ontario Inc. |
Polynucleotides encoding proexendin, and methods and uses thereof
|
US5846937A
(en)
|
1997-03-03 |
1998-12-08 |
1149336 Ontario Inc. |
Method of using exendin and GLP-1 to affect the central nervous system
|
AU7652998A
(en)
|
1997-05-07 |
1998-11-27 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
New cysteine derivatives, processes for their production, and pharmaceuticals containing them
|
BR9811866A
(pt)
|
1997-08-08 |
2000-08-15 |
Amylin Pharmaceuticals Inc |
Compostos agonistas de exendina
|
US7157555B1
(en)
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
NZ504258A
(en)
|
1997-11-14 |
2002-12-20 |
Amylin Pharmaceuticals Inc |
Exendin 3 and 4 agonist compounds for the treatment of diabetes
|
DK1032587T4
(da)
|
1997-11-14 |
2013-04-08 |
Amylin Pharmaceuticals Llc |
Hidtil ukendte exendinagonist-forbindelser
|
US7223725B1
(en)
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
US7220721B1
(en)
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
EP1049486A4
(en)
|
1997-12-05 |
2006-01-04 |
Lilly Co Eli |
GLP-1 FORMULATIONS
|
ATE366115T1
(de)
|
1998-02-13 |
2007-07-15 |
Amylin Pharmaceuticals Inc |
Inotropische und diuretische effekte von exendin und glp-1
|
US6703359B1
(en)
|
1998-02-13 |
2004-03-09 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and GLP-1
|
WO1999043708A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
EP1062240B1
(en)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
N-terminally modified glp-1 derivatives
|
IL138214A0
(en)
|
1998-03-09 |
2001-10-31 |
Zealand Pharmaceuticals As |
Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
DE69918070T2
(de)
|
1998-03-13 |
2005-08-25 |
Novo Nordisk A/S |
Stabilisierte, wässrige Glukagonlösungen, enthaltend Detergenzien
|
WO1999049788A1
(en)
|
1998-03-30 |
1999-10-07 |
Focus Surgery, Inc. |
Ablation system
|
SE9802080D0
(sv)
|
1998-06-11 |
1998-06-11 |
Hellstroem |
Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
|
AU776514B2
(en)
|
1998-08-10 |
2004-09-09 |
General Hospital Corporation, The |
Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof
|
WO2000020592A1
(en)
|
1998-10-07 |
2000-04-13 |
Medical College Of Georgia Research Institute, Inc. |
Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
|
US6284725B1
(en)
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
BR9915961A
(pt)
|
1998-12-07 |
2001-08-21 |
Sod Conseils Rech Applic |
Análogos de glp-1
|
JP4426727B2
(ja)
|
1999-01-14 |
2010-03-03 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
新規なエキセンジンアゴニスト製剤とその投与方法
|
US7399489B2
(en)
|
1999-01-14 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Exendin analog formulations
|
PT1143989E
(pt)
|
1999-01-14 |
2007-03-30 |
Amylin Pharmaceuticals Inc |
Exendinas para supressão de glucagon
|
US6451987B1
(en)
|
1999-03-15 |
2002-09-17 |
Novo Nordisk A/S |
Ion exchange chromatography of proteins and peptides
|
US6451974B1
(en)
|
1999-03-17 |
2002-09-17 |
Novo Nordisk A/S |
Method of acylating peptides and novel acylating agents
|
EP1163211B1
(en)
|
1999-03-17 |
2008-09-24 |
Novo Nordisk A/S |
Method for acylating peptides and proteins
|
US6271241B1
(en)
|
1999-04-02 |
2001-08-07 |
Neurogen Corporation |
Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
|
JP2002544127A
(ja)
|
1999-04-30 |
2002-12-24 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
修飾されたエキセンジンおよびエキセンジン・アゴニスト
|
US6924264B1
(en)
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
US7601691B2
(en)
|
1999-05-17 |
2009-10-13 |
Conjuchem Biotechnologies Inc. |
Anti-obesity agents
|
ATE252601T1
(de)
|
1999-05-17 |
2003-11-15 |
Conjuchem Inc |
Lang wirkende insulinotrope peptide
|
US6506724B1
(en)
|
1999-06-01 |
2003-01-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
|
US6344180B1
(en)
|
1999-06-15 |
2002-02-05 |
Bionebraska, Inc. |
GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
US6586438B2
(en)
|
1999-11-03 |
2003-07-01 |
Bristol-Myers Squibb Co. |
Antidiabetic formulation and method
|
AU775663B2
(en)
|
2000-10-20 |
2004-08-12 |
Amylin Pharmaceuticals, Inc. |
Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
|
GB0121709D0
(en)
|
2001-09-07 |
2001-10-31 |
Imp College Innovations Ltd |
Food inhibition agent
|
AU2002346491A1
(en)
|
2001-12-19 |
2003-07-09 |
Eli Lilly And Company |
Crystalline compositions for controlling blood glucose
|
CZ2004710A3
(cs)
|
2001-12-20 |
2005-02-16 |
Eli Lilly And Company |
Inzulínová sloučenina s protrahovaným účinkem
|
US20030232761A1
(en)
|
2002-03-28 |
2003-12-18 |
Hinke Simon A. |
Novel analogues of glucose-dependent insulinotropic polypeptide
|
EP1837031B1
(en)
|
2002-06-07 |
2009-10-14 |
Waratah Pharmaceuticals, Inc. |
Compositions and methods for treating diabetes
|
CA2490564A1
(en)
|
2002-07-04 |
2004-01-15 |
Zealand Pharma A/S |
Glp-1 and methods for treating diabetes
|
BR0314996A
(pt)
|
2002-10-02 |
2005-08-09 |
Zealand Pharma As |
Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
|
US7192922B2
(en)
|
2002-11-19 |
2007-03-20 |
Allegheny-Singer Research Institute |
Method of treating left ventricular dysfunction
|
GB0300571D0
(en)
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
BRPI0409600A
(pt)
|
2003-04-29 |
2006-04-18 |
Lilly Co Eli |
análogo de insulina, composição, método de tratamento de hiperglicemia, e, análogo de pró-insulina
|
WO2004099246A2
(en)
|
2003-05-09 |
2004-11-18 |
Novo Nordisk A/S |
Peptides for use in treating obesity
|
US7623530B2
(en)
|
2003-11-20 |
2009-11-24 |
Nokia Corporation |
Indication of service flow termination by network control to policy decision function
|
JP2007519642A
(ja)
|
2004-01-30 |
2007-07-19 |
ワラタ ファーマシューティカルズ, インコーポレイテッド |
血糖値を調節するためのglp−1アゴニストとガストリンとの合わせた使用
|
WO2005077072A2
(en)
|
2004-02-11 |
2005-08-25 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
JP5175103B2
(ja)
|
2004-11-12 |
2013-04-03 |
ノヴォ ノルディスク アー/エス |
安定なペプチド製剤
|
TWI362392B
(en)
|
2005-03-18 |
2012-04-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
WO2006121860A2
(en)
|
2005-05-06 |
2006-11-16 |
Bayer Pharmaceuticals Corporation |
Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
|
WO2006134340A2
(en)
|
2005-06-13 |
2006-12-21 |
Imperial Innovations Limited |
Oxyntomodulin analogues and their effects on feeding behaviour
|
US20090202497A1
(en)
|
2005-08-23 |
2009-08-13 |
The General Hospital Corporation |
Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
|
WO2007056362A2
(en)
|
2005-11-07 |
2007-05-18 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
WO2007081824A2
(en)
|
2006-01-06 |
2007-07-19 |
Case Western Reserve University |
Fibrillation resistant proteins
|
WO2007095737A1
(en)
|
2006-02-21 |
2007-08-30 |
Waratah Pharmaceuticals Inc. |
Combination therapy for the treatment of diabetes comprising an exendin agonist and a gastrin compound
|
US7928058B2
(en)
|
2006-02-22 |
2011-04-19 |
Merck Sharp & Dohme Corp. |
Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition
|
CN101622276B
(zh)
|
2006-07-18 |
2015-04-22 |
赛诺菲-安万特 |
用于治疗癌症的抗epha2的拮抗抗体
|
ITMI20061607A1
(it)
|
2006-08-09 |
2008-02-10 |
Maria Vincenza Carriero |
Peptidi con attivita farmacologica
|
WO2008043033A2
(en)
|
2006-10-04 |
2008-04-10 |
Case Western Reserve University |
Fibrillation-resistant insulin and insulin analogues
|
EA023886B1
(ru)
|
2006-11-08 |
2016-07-29 |
Зеаланд Фарма А/С |
Селективные аналоги глюкагонподобного пептида-2 (glp-2)
|
WO2008071010A1
(en)
|
2006-12-12 |
2008-06-19 |
Waratah Pharmaceuticals Inc. |
Combination treatments with selected growth/hormone regulatory factors for diabetes and related diseases
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
MX2009006564A
(es)
|
2007-01-05 |
2009-06-26 |
Univ Indiana Res & Tech Corp |
Analogos de glucagon que muestran solubilidad potenciada en amortiguadores a ph fisiologico.
|
KR20090119876A
(ko)
|
2007-02-15 |
2009-11-20 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
글루카곤/glp-1 수용체 공동-항진물질
|
EP2025684A1
(en)
|
2007-08-15 |
2009-02-18 |
Zealand Pharma A/S |
Glucagon analogues
|
FR2917552B1
(fr)
|
2007-06-15 |
2009-08-28 |
Sagem Defense Securite |
Procede de regulation de la gigue de transmission au sein d'un terminal de reception
|
ATE520714T1
(de)
|
2007-06-15 |
2011-09-15 |
Zealand Pharma As |
Glucagonanaloga
|
EP2679597A1
(en)
|
2007-09-05 |
2014-01-01 |
Novo Nordisk A/S |
Glucagon-like peptide-1 derivatives and their pharmaceutical use
|
EP2930182A1
(en)
|
2007-11-20 |
2015-10-14 |
Ambrx, Inc. |
Modified insulin polypeptides and their uses
|
GB2455553B
(en)
|
2007-12-14 |
2012-10-24 |
Nuaire Ltd |
Motor mounting assembly for an axial fan
|
DE102008003566A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
DE102008003568A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
NZ586589A
(en)
|
2008-01-09 |
2012-04-27 |
Sanofi Aventis Deutschland |
Novel insulin analogues having an extremely delayed time-action profile
|
RU2524423C2
(ru)
|
2008-01-09 |
2014-07-27 |
Санофи-Авентис Дойчланд Гмбх |
Новые производные инсулина с чрезвычайно замедленным профилем время/действие
|
US8993516B2
(en)
|
2008-04-14 |
2015-03-31 |
Case Western Reserve University |
Meal-time insulin analogues of enhanced stability
|
WO2009132129A2
(en)
|
2008-04-22 |
2009-10-29 |
Case Western Reserve University |
Isoform-specific insulin analogues
|
TWI451876B
(zh)
|
2008-06-13 |
2014-09-11 |
Lilly Co Eli |
聚乙二醇化之離脯胰島素化合物
|
SG192405A1
(en)
*
|
2008-06-17 |
2013-08-30 |
Univ Indiana Res & Tech Corp |
Gip-based mixed agonists for treatment of metabolic disorders and obesity
|
WO2009155257A1
(en)
|
2008-06-17 |
2009-12-23 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
|
PA8830501A1
(es)
|
2008-06-17 |
2010-07-27 |
Univ Indiana Res & Tech Corp |
Co-agonistas del receptor de glucagon/glp-1
|
PL219335B1
(pl)
|
2008-07-04 |
2015-04-30 |
Inst Biotechnologii I Antybiotyków |
Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
|
AU2009276346B2
(en)
|
2008-07-31 |
2014-07-03 |
Case Western Reserve University |
Halogen-stabilized insulin
|
US9074014B2
(en)
|
2008-08-07 |
2015-07-07 |
Ipsen Pharma S.A.S. |
Analogues of glucose-dependent insulinotropic polypeptide
|
EP2340049B1
(en)
|
2008-09-12 |
2015-11-11 |
Novo Nordisk A/S |
Method of acylating a peptide or protein
|
CA2747155A1
(en)
|
2008-12-15 |
2010-06-24 |
Zealand Pharma A/S |
Glucagon analogues
|
CN102292348B
(zh)
|
2008-12-15 |
2015-07-08 |
西兰制药公司 |
胰高血糖素类似物
|
PL2370460T3
(pl)
|
2008-12-15 |
2014-09-30 |
Zealand Pharma As |
Analogi glukagonu
|
KR20110126589A
(ko)
|
2008-12-15 |
2011-11-23 |
질랜드 파마 에이/에스 |
글루카곤 유사체
|
AU2009335715B2
(en)
|
2008-12-19 |
2016-09-15 |
Indiana University Research And Technology Corporation |
Amide-based insulin prodrugs
|
US8481485B2
(en)
|
2008-12-19 |
2013-07-09 |
Indiana University Research And Technology Corporation |
Insulin analogs
|
WO2010096052A1
(en)
|
2009-02-19 |
2010-08-26 |
Merck Sharp & Dohme Corp. |
Oxyntomodulin analogs
|
WO2010107487A2
(en)
|
2009-03-18 |
2010-09-23 |
Wu Nian |
Lipid-drug conjugates for drug delivery
|
CN101519446A
(zh)
|
2009-03-31 |
2009-09-02 |
上海一就生物医药有限公司 |
一种重组人胰岛素及其类似物的制备方法
|
SG176858A1
(en)
|
2009-06-16 |
2012-02-28 |
Univ Indiana Res & Tech Corp |
Gip receptor-active glucagon compounds
|
AP3329A
(en)
|
2009-07-13 |
2015-06-30 |
Zealand Pharma As |
Acylated glucagon analogues
|
CA2784757A1
(en)
|
2009-12-16 |
2011-07-07 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
US20110312881A1
(en)
|
2009-12-21 |
2011-12-22 |
Amunix, Inc. |
Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
|
CN102892425A
(zh)
|
2010-01-20 |
2013-01-23 |
西兰制药公司 |
心脏病症的治疗
|
EP2528618A4
(en)
|
2010-01-27 |
2015-05-27 |
Univ Indiana Res & Tech Corp |
GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
|
JP2013523620A
(ja)
|
2010-03-26 |
2013-06-17 |
ノヴォ ノルディスク アー/エス |
新規のグルカゴンアナログ
|
RU2559320C2
(ru)
*
|
2010-03-26 |
2015-08-10 |
Ново Нордиск А/С |
Новые аналоги глюкагона
|
AR080592A1
(es)
|
2010-03-26 |
2012-04-18 |
Lilly Co Eli |
Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
|
CN103003300B
(zh)
|
2010-04-27 |
2017-06-09 |
西兰制药公司 |
Glp‑1受体激动剂和胃泌素的肽缀合物及其用途
|
WO2011134284A1
(zh)
|
2010-04-27 |
2011-11-03 |
浙江贝达药业有限公司 |
胰高血糖素样肽-1类似物及其应用
|
UY33462A
(es)
|
2010-06-23 |
2012-01-31 |
Zealand Pharma As |
Analogos de glucagon
|
AP2013006671A0
(en)
|
2010-06-24 |
2013-01-31 |
Zealand Pharma As |
Glucagon analogues
|
WO2012062803A1
(en)
|
2010-11-09 |
2012-05-18 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
AU2012208349A1
(en)
|
2011-01-20 |
2013-07-18 |
Zealand Pharma A/S |
Combination of acylated glucagon analogues with insulin analogues
|
CA2830974A1
(en)
|
2011-03-28 |
2012-10-04 |
Jesper F. Lau |
Novel glucagon analogues
|
US9790262B2
(en)
|
2011-04-05 |
2017-10-17 |
Longevity Biotech, Inc. |
Compositions comprising glucagon analogs and methods of making and using the same
|
ES2612278T3
(es)
|
2011-04-12 |
2017-05-16 |
Novo Nordisk A/S |
Derivados de GLP-1 doble-acilados
|
WO2012150503A2
(en)
|
2011-05-03 |
2012-11-08 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
EP2707713A2
(en)
*
|
2011-05-10 |
2014-03-19 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
JP5914641B2
(ja)
|
2011-06-10 |
2016-05-11 |
ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドBeijing Hanmi Pharmaceutical Co., Ltd. |
グルコース依存性インスリン分泌刺激ポリペプチドのアナログ、医薬組成物及びその使用
|
KR20140070612A
(ko)
|
2011-09-23 |
2014-06-10 |
노보 노르디스크 에이/에스 |
신규 글루카곤 유사체
|
MX2014005351A
(es)
|
2011-11-03 |
2014-05-28 |
Zealand Pharma As |
Conjugados de gastrina peptidicos de agonistas de receptor glp-1.
|
AP2014007797A0
(en)
|
2011-12-23 |
2014-07-31 |
Boehringer Ingelheim Int |
Glucagon analogues
|
AR090937A1
(es)
|
2012-05-03 |
2014-12-17 |
Zealand Pharma As |
Compuestos agonista duales de gip-glp-1 y metodos para usarlos
|
TR201802689T4
(tr)
|
2012-05-03 |
2018-03-21 |
Zealand Pharma As |
Glukagon benzeri peptit-2 (glp-2) analogları.
|
WO2013192131A1
(en)
|
2012-06-21 |
2013-12-27 |
Indiana University Research And Technology Corporation |
Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
|
CN109456400A
(zh)
|
2012-07-23 |
2019-03-12 |
西兰制药公司 |
胰高血糖素类似物
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
WO2014096150A1
(en)
*
|
2012-12-21 |
2014-06-26 |
Sanofi |
Dual glp1/gip or trigonal glp1/gip/glucagon agonists
|
CA2902352A1
(en)
*
|
2013-03-14 |
2014-09-18 |
Medimmune Limited |
Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
|
PT3057984T
(pt)
|
2013-10-17 |
2018-10-24 |
Boehringer Ingelheim Int |
Análogos de glucagon acilados
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
CN105849122B
(zh)
|
2013-11-06 |
2021-04-30 |
西兰制药公司 |
Gip-glp-1双重激动剂化合物及方法
|
CA2929107C
(en)
*
|
2013-11-06 |
2023-09-26 |
Zealand Pharma A/S |
Glucagon-glp-1-gip triple agonist compounds
|
WO2015086730A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
WO2015124612A1
(en)
|
2014-02-18 |
2015-08-27 |
Novo Nordisk A/S |
Stable glucagon analogues and use for treatment of hypoglycaemia
|
EP3985016A1
(en)
|
2014-10-29 |
2022-04-20 |
Zealand Pharma A/S |
Gip agonist compounds and methods
|
US10336802B2
(en)
|
2015-04-16 |
2019-07-02 |
Zealand Pharma A/S |
Acylated glucagon analogue
|